Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Preventing type 2 diabetes mellitus: is metformin the answer?

Nature Reviews Endocrinology volume 6, pages 253–254 (2010)Cite this article

Subjects

Most individuals with prediabetes—defined by the presence of impaired glucose levels—are overweight or obese and could benefit from lifestyle changes to lose weight and reduce their risk of developing type 2 diabetes mellitus (T2DM). As lifestyle interventions are hard to implement and not effective over the long term in most individuals, could additional intervention with pharmacotherapy be warranted for the prevention of T2DM?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nathan, D. M. et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30, 753–759 (2007).

    Article  CAS  Google Scholar 

  2. Rhee, M. K. et al. Many Americans have prediabetes and should be considered for metformin therapy. Diabetes Care 33, 49–54 (2010).

    Article  CAS  Google Scholar 

  3. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).

    Article  CAS  Google Scholar 

  4. Buchanan, T. A. et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51, 2796–2803 (2002).

    Article  CAS  Google Scholar 

  5. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. Lancet 368, 1096–1105 (2006).

  6. Chaisson, J. L. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072–2077 (2002).

    Article  Google Scholar 

  7. Torgerson, J. S., Hauptman, J., Boldrin, M. N. & Sjöström, L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27, 155–161 (2004).

    Article  CAS  Google Scholar 

  8. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26, 977–980 (2003).

  9. Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343–1350 (2001).

    Article  CAS  Google Scholar 

  10. Xiang, A. et al. Effect of pioglitazone on pancreatic beta cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55, 517–522 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Keck School of Medicine of the University of Southern California, 3 North University Hospital, 1500 San Pablo Street, Los Angeles, 90033, CA, USA

    Thomas A. Buchanan

  2. Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Avenue, 5th Floor, Pasadena, 91101, CA, USA

    Anny H. Xiang

Authors
  1. Thomas A. Buchanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anny H. Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas A. Buchanan.

Ethics declarations

Competing interests

T. A. Buchanan declares associations with the following companies: Eli Lilly (speakers bureau), Takeda Pharmaceuticals North America (consultant, speakers bureau, grant/research support) Tethys Bioscience (consultant, stockholer). A. H. Xiang declares associations with the following companies: Takeda Pharmaceuticals North America (grant/research support), Tethys Bioscience (consultant).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buchanan, T., Xiang, A. Preventing type 2 diabetes mellitus: is metformin the answer?. Nat Rev Endocrinol 6, 253–254 (2010). https://doi.org/10.1038/nrendo.2010.25

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2010.25

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing